On Friday, C4 Therapeutics Inc (NASDAQ: CCCC) was 5.25% up from the session before settling in for the closing price of $5.33. A 52-week range for CCCC has been $1.06 – $11.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 7.65%. When this article was written, the company’s average yearly earnings per share was at 44.36%. With a float of $58.32 million, this company’s outstanding shares have now reached $60.47 million.
Considering the fact that the conglomerate employs 145 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 76.78%, operating margin of -354.44%, and the pretax margin is -312.52%.
C4 Therapeutics Inc (CCCC) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward C4 Therapeutics Inc stocks. The insider ownership of C4 Therapeutics Inc is 17.28%, while institutional ownership is 80.98%. The most recent insider transaction that took place on Oct 18 ’24, was worth 83,321. Before that another transaction happened on Oct 11 ’24, when Company’s Director proposed sale 8,561 for $5.38, making the entire transaction worth $46,061.
C4 Therapeutics Inc (CCCC) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.7 earnings per share (EPS) during the time that was less than consensus figure (set at -0.68) by -0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.43 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 44.36% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.30% during the next five years compared to -36.05% drop over the previous five years of trading.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
You can see what C4 Therapeutics Inc (CCCC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.31. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.70, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -1.73 in one year’s time.
Technical Analysis of C4 Therapeutics Inc (CCCC)
Compared to the last year’s volume of 2.17 million, its volume of 0.67 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 14.64%. Additionally, its Average True Range was 0.42.
During the past 100 days, C4 Therapeutics Inc’s (CCCC) raw stochastic average was set at 45.33%, which indicates a significant increase from 20.23% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 77.89% in the past 14 days, which was lower than the 83.04% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.01, while its 200-day Moving Average is $6.46. Nevertheless, the first resistance level for the watch stands at $5.90 in the near term. At $6.19, the stock is likely to face the second major resistance level. The third major resistance level sits at $6.42. If the price goes on to break the first support level at $5.38, it is likely to go to the next support level at $5.15. Now, if the price goes above the second support level, the third support stands at $4.86.
C4 Therapeutics Inc (NASDAQ: CCCC) Key Stats
There are 69,338K outstanding shares of the company, which has a market capitalization of 416.80 million. As of now, sales total 20,760 K while income totals -132,490 K. Its latest quarter income was 12,010 K while its last quarter net income were -17,720 K.
